M&A Deal Summary |
|
|---|---|
| Date | 2022-06-03 |
| Target | Turning Point Therapeutics |
| Sector | Life Science |
| Buyer(s) |
HBM Partners AG
Bristol-Myers Squibb |
| Deal Type | Add-on Acquisition |
| Deal Value | 4.1B USD |
| Advisor(s) | Goldman Sachs (Financial) Cooley LLP (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.0B USD |
| Size | Mega |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 64 of 65 |
| Sector (Life Science) | 54 of 55 |
| Type (Add-on Acquisition) | 2 of 2 |
| State (California) | 17 of 17 |
| Country (United States) | 43 of 44 |
| Year (2022) | 3 of 4 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-03-28 |
Aculys Pharma
Minato-ku, Japan Aculys Pharma is a biopharmaceutical company focused on the development and commercialization of innovations in the fields of neurology and psychiatry. Aculys Pharma was founded in 2021 and is based in Minato-ku, Japan. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-08 |
Mineralys Therapeutics
Radnor, Pennsylvania, United States Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the company is initially developing for the treatment of patients with uncontrolled hypertension. Mineralys Therapeutics was founded in 2020 and is based in Radnor, Pennsylvania. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1887 |
| Sector | Life Science |
| Employees | 32,200 |
| Revenue | 46.2B USD (2022) |
Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes. The majority of Bristol-Myers Squibb's revenue comes from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and metabolics. Bristol-Myers Squibb was incorporated in 1887 and is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 20 of 23 |
| Sector (Life Science) | 20 of 23 |
| Type (Add-on Acquisition) | 19 of 21 |
| State (California) | 7 of 9 |
| Country (United States) | 17 of 20 |
| Year (2022) | 1 of 1 |
| Size (of disclosed) | 8 of 19 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-08-03 |
Bristol-Myers Squibb - Drug Product Manufacturing Facility
Couvet, Switzerland Bristol-Myers Squibb Co.'s Drug Product Manufacturing Facility provides flexible state-of-the-art tablet & capsule manufacturing and packaging services. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-10-08 |
Mirati Therapeutics
San Diego, California, United States Mirati Therapeutics is a commercial-stage biotechnology company whose mission is to discover, design, and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati Therapeutics is based in San Diego, California. |
Buy | $4.8B |
